Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG

The aim of this study was to describe the baseline demographic and clinical characteristics as well as the functional status of a prospective cohort of patients with rheumatic diseases assisted by the Brazilian Public Health System (SUS). Data for 302 patients receiving tumor necrosis factor α inhibitors (anti-TNF agents) was collected through a standard form. Among patients, 229 (75.8%) were female and 155 (51.3%) were Caucasian; the mean age was 50.3 ± 12.8 years, and the mean disease duration was 9.9 ± 8.7 years. Among them 214 patients (70.9%) received adalimumab, 72 (23.8%) etanercept, and 16 (5.3%) infliximab. Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) was 1.37 ± 0.67 for all participants. Poor functional response was associated with female gender, married patients and with a score of < 0.6 on the EuroQoL-5 dimensions (EQ-5D). Significant correlation was found between the HAQ-DI values, disease activity and quality of life (QOL). The results obtained in this study contribute to a better understanding of the clinical and demographic characteristics of patients with rheumatic diseases at the beginning of anti-TNF-agent treatment by SUS. Furthermore, our findings are consistent with another Brazilian and foreign cross-sectional investigations. This knowledge can be of great importance for further studies evaluating the effectiveness of biological agents, as well as, to contribute to improve the well-being of the patients with rheumatic diseases.

Saved in:
Bibliographic Details
Main Authors: Oliveira Junior,Haliton Alves de, Almeida,Alessandra Maciel, Acurcio,Francisco Assis, Santos,Jéssica Barreto dos, Kakehasi,Adriana Maria, Alvares,Juliana, Dabés,Clarice Gomes e Souza, Cherchiglia,Mariangela Leal
Format: Digital revista
Language:English
Published: Universidade de São Paulo, Faculdade de Ciências Farmacêuticas 2015
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502015000300709
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1984-82502015000300709
record_format ojs
spelling oai:scielo:S1984-825020150003007092015-11-23Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MGOliveira Junior,Haliton Alves deAlmeida,Alessandra MacielAcurcio,Francisco AssisSantos,Jéssica Barreto dosKakehasi,Adriana MariaAlvares,JulianaDabés,Clarice Gomes e SouzaCherchiglia,Mariangela Leal Rheumatic diseases/treatment/patients profile Rheumatoid arthritis Ankylosing spondylitis Psoriatic arthritis Brazilian public health system Anti-TNF agents/treatment of rheumatic diseases The aim of this study was to describe the baseline demographic and clinical characteristics as well as the functional status of a prospective cohort of patients with rheumatic diseases assisted by the Brazilian Public Health System (SUS). Data for 302 patients receiving tumor necrosis factor α inhibitors (anti-TNF agents) was collected through a standard form. Among patients, 229 (75.8%) were female and 155 (51.3%) were Caucasian; the mean age was 50.3 ± 12.8 years, and the mean disease duration was 9.9 ± 8.7 years. Among them 214 patients (70.9%) received adalimumab, 72 (23.8%) etanercept, and 16 (5.3%) infliximab. Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) was 1.37 ± 0.67 for all participants. Poor functional response was associated with female gender, married patients and with a score of < 0.6 on the EuroQoL-5 dimensions (EQ-5D). Significant correlation was found between the HAQ-DI values, disease activity and quality of life (QOL). The results obtained in this study contribute to a better understanding of the clinical and demographic characteristics of patients with rheumatic diseases at the beginning of anti-TNF-agent treatment by SUS. Furthermore, our findings are consistent with another Brazilian and foreign cross-sectional investigations. This knowledge can be of great importance for further studies evaluating the effectiveness of biological agents, as well as, to contribute to improve the well-being of the patients with rheumatic diseases.info:eu-repo/semantics/openAccessUniversidade de São Paulo, Faculdade de Ciências FarmacêuticasBrazilian Journal of Pharmaceutical Sciences v.51 n.3 20152015-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502015000300709en10.1590/S1984-82502015000300023
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Oliveira Junior,Haliton Alves de
Almeida,Alessandra Maciel
Acurcio,Francisco Assis
Santos,Jéssica Barreto dos
Kakehasi,Adriana Maria
Alvares,Juliana
Dabés,Clarice Gomes e Souza
Cherchiglia,Mariangela Leal
spellingShingle Oliveira Junior,Haliton Alves de
Almeida,Alessandra Maciel
Acurcio,Francisco Assis
Santos,Jéssica Barreto dos
Kakehasi,Adriana Maria
Alvares,Juliana
Dabés,Clarice Gomes e Souza
Cherchiglia,Mariangela Leal
Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG
author_facet Oliveira Junior,Haliton Alves de
Almeida,Alessandra Maciel
Acurcio,Francisco Assis
Santos,Jéssica Barreto dos
Kakehasi,Adriana Maria
Alvares,Juliana
Dabés,Clarice Gomes e Souza
Cherchiglia,Mariangela Leal
author_sort Oliveira Junior,Haliton Alves de
title Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG
title_short Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG
title_full Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG
title_fullStr Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG
title_full_unstemmed Profile of patients with rheumatic diseases undergoing treatment with anti-TNF agents in the Brazilian Public Health System (SUS), Belo Horizonte - MG
title_sort profile of patients with rheumatic diseases undergoing treatment with anti-tnf agents in the brazilian public health system (sus), belo horizonte - mg
description The aim of this study was to describe the baseline demographic and clinical characteristics as well as the functional status of a prospective cohort of patients with rheumatic diseases assisted by the Brazilian Public Health System (SUS). Data for 302 patients receiving tumor necrosis factor α inhibitors (anti-TNF agents) was collected through a standard form. Among patients, 229 (75.8%) were female and 155 (51.3%) were Caucasian; the mean age was 50.3 ± 12.8 years, and the mean disease duration was 9.9 ± 8.7 years. Among them 214 patients (70.9%) received adalimumab, 72 (23.8%) etanercept, and 16 (5.3%) infliximab. Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) was 1.37 ± 0.67 for all participants. Poor functional response was associated with female gender, married patients and with a score of < 0.6 on the EuroQoL-5 dimensions (EQ-5D). Significant correlation was found between the HAQ-DI values, disease activity and quality of life (QOL). The results obtained in this study contribute to a better understanding of the clinical and demographic characteristics of patients with rheumatic diseases at the beginning of anti-TNF-agent treatment by SUS. Furthermore, our findings are consistent with another Brazilian and foreign cross-sectional investigations. This knowledge can be of great importance for further studies evaluating the effectiveness of biological agents, as well as, to contribute to improve the well-being of the patients with rheumatic diseases.
publisher Universidade de São Paulo, Faculdade de Ciências Farmacêuticas
publishDate 2015
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502015000300709
work_keys_str_mv AT oliveirajuniorhalitonalvesde profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg
AT almeidaalessandramaciel profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg
AT acurciofranciscoassis profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg
AT santosjessicabarretodos profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg
AT kakehasiadrianamaria profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg
AT alvaresjuliana profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg
AT dabesclaricegomesesouza profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg
AT cherchigliamariangelaleal profileofpatientswithrheumaticdiseasesundergoingtreatmentwithantitnfagentsinthebrazilianpublichealthsystemsusbelohorizontemg
_version_ 1756437794813640704